Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke A Probst

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
The New England Journal of Medicine|February 23, 2017
Pediatric Drug Formulations - Unintended Consequences of LegislationLuke A Probst, Thomas R Welch
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|November 3, 2012
Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costsManika Suryadevara, Kelly E Steidl, Luke A Probst, et al.
The Annals of Pharmacotherapy|November 22, 2013
Evaluation of dabigatran utilization and risk among hospitalized patientsEric Sidman, Luke A Probst, William Darko, et al.
P & T : a Peer-Reviewed Journal for Formulary Management|September 6, 2019
Andexanet Alfa: Preferred Treatment or Therapeutic Option?Curtis A Blow, Luke A Probst, Christopher D Miller, et al.
Hospital Pharmacy|March 28, 2018
Changes in Pharmacy Residency Training Design Between 2012 and 2017: A Perspective of Academic Medical CentersAnne Krasniak, William Darko, Christopher D Miller, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 5, 2010
Rhabdomyolysis associated with phentermineKelly E Steidl, William Darko, Luke A Probst, et al.
P & T : a Peer-Reviewed Journal for Formulary Management|September 6, 2019
Evaluation of Warfarin Patients with Low Time in Therapeutic Range (TTR) for Transition to Non-Vitamin-K Oral Anticoagulant (NOAC) TherapyLindsey M Fovel, Christopher D Miller, Robert W Seabury, et al.
P & T : a Peer-Reviewed Journal for Formulary Management|June 5, 2019
Evaluation of Warfarin Patients with Low Time in Therapeutic Range (TTR) for Transition to Non-Vitamin-K Oral Anticoagulant (NOAC) TherapyLindsey M Fovel, Christopher D Miller, Robert W Seabury, et al.
The Annals of Pharmacotherapy|June 26, 2020
Recurrent Renal Dysfunction Secondary to Probable Piperacillin-Tazobactam-Induced Acute Interstitial NephritisKatie A Parsels, Robert W Seabury, William Darko, et al.
Hospital Pharmacy|January 28, 2020
Evaluation of a Long-Acting Opioid Restriction Policy: Does Restriction Reduce the Need for Naloxone Reversal?Jenna L Fancher, Robert W Seabury, William Darko, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|February 23, 2017
Pediatric Drug Formulations - Unintended Consequences of LegislationLuke A Probst, Thomas R Welch
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|November 3, 2012
Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costsManika Suryadevara, Kelly E Steidl, Luke A Probst, et al.
The Annals of Pharmacotherapy|November 22, 2013
Evaluation of dabigatran utilization and risk among hospitalized patientsEric Sidman, Luke A Probst, William Darko, et al.
P & T : a Peer-Reviewed Journal for Formulary Management|September 6, 2019
Andexanet Alfa: Preferred Treatment or Therapeutic Option?Curtis A Blow, Luke A Probst, Christopher D Miller, et al.
Hospital Pharmacy|March 28, 2018
Changes in Pharmacy Residency Training Design Between 2012 and 2017: A Perspective of Academic Medical CentersAnne Krasniak, William Darko, Christopher D Miller, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 5, 2010
Rhabdomyolysis associated with phentermineKelly E Steidl, William Darko, Luke A Probst, et al.
P & T : a Peer-Reviewed Journal for Formulary Management|September 6, 2019
Evaluation of Warfarin Patients with Low Time in Therapeutic Range (TTR) for Transition to Non-Vitamin-K Oral Anticoagulant (NOAC) TherapyLindsey M Fovel, Christopher D Miller, Robert W Seabury, et al.
P & T : a Peer-Reviewed Journal for Formulary Management|June 5, 2019
Evaluation of Warfarin Patients with Low Time in Therapeutic Range (TTR) for Transition to Non-Vitamin-K Oral Anticoagulant (NOAC) TherapyLindsey M Fovel, Christopher D Miller, Robert W Seabury, et al.
The Annals of Pharmacotherapy|June 26, 2020
Recurrent Renal Dysfunction Secondary to Probable Piperacillin-Tazobactam-Induced Acute Interstitial NephritisKatie A Parsels, Robert W Seabury, William Darko, et al.
Hospital Pharmacy|January 28, 2020
Evaluation of a Long-Acting Opioid Restriction Policy: Does Restriction Reduce the Need for Naloxone Reversal?Jenna L Fancher, Robert W Seabury, William Darko, et al.
Pageof 3